Loading
A phase 3 trial testing SCTB35 in follicular lymphoma, now recruiting.
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT07562022, led by Sinocelltech, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma. Planned enrolment is 93 participants (estimated). The study started in 2026-06-09 and primary completion is expected in 2028-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/